Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2003 Dec;111(16):1892–1901. doi: 10.1289/ehp.6316

Perfluorooctanesulfonate and other fluorochemicals in the serum of American Red Cross adult blood donors.

Geary W Olsen 1, Timothy R Church 1, John P Miller 1, Jean M Burris 1, Kristen J Hansen 1, James K Lundberg 1, John B Armitage 1, Ross M Herron 1, Zahra Medhdizadehkashi 1, John B Nobiletti 1, E Mary O'Neill 1, Jeffrey H Mandel 1, Larry R Zobel 1
PMCID: PMC1241763  PMID: 14644663

Abstract

Perfluorooctanesulfonyl fluoride-based products have included surfactants, paper and packaging treatments, and surface protectants (e.g., for carpet, upholstery, textile). Depending on the specific functional derivatization or degree of polymerization, such products may degrade or metabolize, to an undetermined degree, to perfluorooctanesulfonate (PFOS), a stable and persistent end product that has the potential to bioaccumulate. In this investigation, a total of 645 adult donor serum samples from six American Red Cross blood collection centers were analyzed for PFOS and six other fluorochemicals using HPLC-electrospray tandem mass spectrometry. PFOS concentrations ranged from the lower limit of quantitation of 4.1 ppb to 1656.0 ppb with a geometric mean of 34.9 ppb [95% confidence interval (CI), 33.3-36.5]. The geometric mean was higher among males (37.8 ppb; 95% CI, 35.5-40.3) than among females (31.3 ppb; 95% CI, 30.0-34.3). No substantial difference was observed with age. The estimate of the 95% tolerance limit of PFOS was 88.5 ppb (upper limit of 95% CI, 100.0 ppb). The measures of central tendency for the other fluorochemicals (N-ethyl perfluorooctanesulfonamidoacetate, N-methyl perfluorooctanesulfonamidoacetate, perfluorooctanesulfonamidoacetate, perfluorooctanesulfonamide, perfluorooctanoate, and perfluorohexanesulfonate) were approximately an order of magnitude lower than PFOS. Because serum PFOS concentrations correlate with cumulative human exposure, this information can be useful for risk characterization.

Full Text

The Full Text of this article is available as a PDF (260.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen J., Butler D. D. Assessing the effects of donor knowledge and perceived risk on intentions to donate blood. J Health Care Mark. 1993 Fall;13(3):26–33. [PubMed] [Google Scholar]
  2. Andaleeb S. S., Basu A. K. Explaining blood donation: the trust factor. J Health Care Mark. 1995 Spring;15(1):42–48. [PubMed] [Google Scholar]
  3. Belisle J. Organic fluorine in human serum: natural versus industrial sources. Science. 1981 Jun 26;212(4502):1509–1510. doi: 10.1126/science.7233235. [DOI] [PubMed] [Google Scholar]
  4. Berthiaume Jessica, Wallace Kendall B. Perfluorooctanoate, perflourooctanesulfonate, and N-ethyl perfluorooctanesulfonamido ethanol; peroxisome proliferation and mitochondrial biogenesis. Toxicol Lett. 2002 Mar 24;129(1-2):23–32. doi: 10.1016/s0378-4274(01)00466-0. [DOI] [PubMed] [Google Scholar]
  5. Biegel L. B., Hurtt M. E., Frame S. R., O'Connor J. C., Cook J. C. Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol Sci. 2001 Mar;60(1):44–55. doi: 10.1093/toxsci/60.1.44. [DOI] [PubMed] [Google Scholar]
  6. Biegel L. B., Liu R. C., Hurtt M. E., Cook J. C. Effects of ammonium perfluorooctanoate on Leydig cell function: in vitro, in vivo, and ex vivo studies. Toxicol Appl Pharmacol. 1995 Sep;134(1):18–25. doi: 10.1006/taap.1995.1164. [DOI] [PubMed] [Google Scholar]
  7. Burnett J. J. Examining the profiles of the donor and nondonor through a multiple discriminant approach. Transfusion. 1982 Mar-Apr;22(2):138–142. doi: 10.1046/j.1537-2995.1982.22282177121.x. [DOI] [PubMed] [Google Scholar]
  8. Butenhoff John, Costa Giovanni, Elcombe Cliff, Farrar David, Hansen Kristin, Iwai Hiroyuki, Jung Reinhard, Kennedy Gerald, Jr, Lieder Paul, Olsen Geary. Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. Toxicol Sci. 2002 Sep;69(1):244–257. doi: 10.1093/toxsci/69.1.244. [DOI] [PubMed] [Google Scholar]
  9. Chiavetta J., Ennis M., Gula C. A., Baker A. D., Chambers T. L. Test-seeking as motivation in volunteer blood donors. Transfus Med Rev. 2000 Jul;14(3):205–215. doi: 10.1053/tm.2000.7353. [DOI] [PubMed] [Google Scholar]
  10. Cohen S. M. Urinary bladder carcinogenesis. Toxicol Pathol. 1998 Jan-Feb;26(1):121–127. doi: 10.1177/019262339802600114. [DOI] [PubMed] [Google Scholar]
  11. Cook J. C., Klinefelter G. R., Hardisty J. F., Sharpe R. M., Foster P. M. Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms, and relevance to humans. Crit Rev Toxicol. 1999 Mar;29(2):169–261. doi: 10.1080/10408449991349203. [DOI] [PubMed] [Google Scholar]
  12. Cook J. C., Murray S. M., Frame S. R., Hurtt M. E. Induction of Leydig cell adenomas by ammonium perfluorooctanoate: a possible endocrine-related mechanism. Toxicol Appl Pharmacol. 1992 Apr;113(2):209–217. doi: 10.1016/0041-008x(92)90116-a. [DOI] [PubMed] [Google Scholar]
  13. Giesy J. P., Kannan K. Global distribution of perfluorooctane sulfonate in wildlife. Environ Sci Technol. 2001 Apr 1;35(7):1339–1342. doi: 10.1021/es001834k. [DOI] [PubMed] [Google Scholar]
  14. Gilliland F. D., Mandel J. S. Mortality among employees of a perfluorooctanoic acid production plant. J Occup Med. 1993 Sep;35(9):950–954. doi: 10.1097/00043764-199309000-00020. [DOI] [PubMed] [Google Scholar]
  15. Hagen D. F., Belisle J., Johnson J. D., Venkateswarlu P. Characterization of fluorinated metabolites by a gas chromatographic-helium microwave plasma detector--the biotransformation of 1H, 1H, 2H, 2H-perfluorodecanol to perfluorooctanoate. Anal Biochem. 1981 Dec;118(2):336–343. doi: 10.1016/0003-2697(81)90591-1. [DOI] [PubMed] [Google Scholar]
  16. Hansen K. J., Clemen L. A., Ellefson M. E., Johnson H. O. Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. Environ Sci Technol. 2001 Feb 15;35(4):766–770. doi: 10.1021/es001489z. [DOI] [PubMed] [Google Scholar]
  17. Hansen K. J., Johnson H. O., Eldridge J. S., Butenhoff J. L., Dick L. A. Quantitative characterization of trace levels of PFOS and PFOA in the Tennessee River. Environ Sci Technol. 2002 Apr 15;36(8):1681–1685. doi: 10.1021/es010780r. [DOI] [PubMed] [Google Scholar]
  18. Haughom B., Spydevold O. The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. Biochim Biophys Acta. 1992 Sep 22;1128(1):65–72. doi: 10.1016/0005-2760(92)90258-w. [DOI] [PubMed] [Google Scholar]
  19. Hu Wenyue, Jones Paul D., Upham Brad L., Trosko James E., Lau Christopher, Giesy John P. Inhibition of gap junctional intercellular communication by perfluorinated compounds in rat liver and dolphin kidney epithelial cell lines in vitro and Sprague-Dawley rats in vivo. Toxicol Sci. 2002 Aug;68(2):429–436. doi: 10.1093/toxsci/68.2.429. [DOI] [PubMed] [Google Scholar]
  20. Kannan K., Franson J. C., Bowerman W. W., Hansen K. J., Jones P. D., Giesy J. P. Perfluorooctane sulfonate in fish-eating water birds including bald eagles and albatrosses. Environ Sci Technol. 2001 Aug 1;35(15):3065–3070. doi: 10.1021/es001935i. [DOI] [PubMed] [Google Scholar]
  21. Kannan K., Koistinen J., Beckmen K., Evans T., Gorzelany J. F., Hansen K. J., Jones P. D., Helle E., Nyman M., Giesy J. P. Accumulation of perfluorooctane sulfonate in marine mammals. Environ Sci Technol. 2001 Apr 15;35(8):1593–1598. doi: 10.1021/es001873w. [DOI] [PubMed] [Google Scholar]
  22. Kannan Kurunthachalam, Corsolini Simonetta, Falandysz Jerzy, Oehme Günter, Focardi Silvano, Giesy John P. Perfluorooctanesulfonate and related fluorinated hydrocarbons in marine mammals, fishes, and birds from coasts of the Baltic and the Mediterranean Seas. Environ Sci Technol. 2002 Aug 1;36(15):3210–3216. doi: 10.1021/es020519q. [DOI] [PubMed] [Google Scholar]
  23. Kannan Kurunthachalam, Newsted John, Halbrook Richard S., Giesy John P. Perfluorooctanesulfonate and related fluorinated hydrocarbons in mink and river otters from the United States. Environ Sci Technol. 2002 Jun 15;36(12):2566–2571. doi: 10.1021/es0205028. [DOI] [PubMed] [Google Scholar]
  24. Keller B. J., Marsman D. S., Popp J. A., Thurman R. G. Several nongenotoxic carcinogens uncouple mitochondrial oxidative phosphorylation. Biochim Biophys Acta. 1992 Sep 25;1102(2):237–244. doi: 10.1016/0005-2728(92)90105-b. [DOI] [PubMed] [Google Scholar]
  25. Lau Christopher, Thibodeaux Julie R., Hanson Roger G., Rogers John M., Grey Brian E., Stanton Mark E., Butenhoff John L., Stevenson Lisa A. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II: postnatal evaluation. Toxicol Sci. 2003 May 28;74(2):382–392. doi: 10.1093/toxsci/kfg122. [DOI] [PubMed] [Google Scholar]
  26. Leibrecht B. C., Hogan J. M., Luz G. A., Tobias K. I. Donor and nondonor motivations. Transfusion. 1976 Mar-Apr;16(2):182–189. doi: 10.1046/j.1537-2995.1976.16276155116.x. [DOI] [PubMed] [Google Scholar]
  27. Luebker Deanna J., Hansen Kris J., Bass Nathan M., Butenhoff John L., Seacat Andrew M. Interactions of fluorochemicals with rat liver fatty acid-binding protein. Toxicology. 2002 Jul 15;176(3):175–185. doi: 10.1016/s0300-483x(02)00081-1. [DOI] [PubMed] [Google Scholar]
  28. Martin Jonathan W., Muir Derek C. G., Moody Cheryl A., Ellis David A., Kwan Wai Chi, Solomon Keith R., Mabury Scott A. Collection of airborne fluorinated organics and analysis by gas chromatography/chemical ionization mass spectrometry. Anal Chem. 2002 Feb 1;74(3):584–590. doi: 10.1021/ac015630d. [DOI] [PubMed] [Google Scholar]
  29. Obourn J. D., Frame S. R., Bell R. H., Jr, Longnecker D. S., Elliott G. S., Cook J. C. Mechanisms for the pancreatic oncogenic effects of the peroxisome proliferator Wyeth-14,643. Toxicol Appl Pharmacol. 1997 Aug;145(2):425–436. doi: 10.1006/taap.1997.8210. [DOI] [PubMed] [Google Scholar]
  30. Olsen G. W., Burris J. M., Burlew M. M., Mandel J. H. Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers. Drug Chem Toxicol. 2000 Nov;23(4):603–620. doi: 10.1081/dct-100101973. [DOI] [PubMed] [Google Scholar]
  31. Olsen G. W., Burris J. M., Mandel J. H., Zobel L. R. Serum perfluorooctane sulfonate and hepatic and lipid clinical chemistry tests in fluorochemical production employees. J Occup Environ Med. 1999 Sep;41(9):799–806. doi: 10.1097/00043764-199909000-00012. [DOI] [PubMed] [Google Scholar]
  32. Olsen G. W., Gilliland F. D., Burlew M. M., Burris J. M., Mandel J. S., Mandel J. H. An epidemiologic investigation of reproductive hormones in men with occupational exposure to perfluorooctanoic acid. J Occup Environ Med. 1998 Jul;40(7):614–622. doi: 10.1097/00043764-199807000-00006. [DOI] [PubMed] [Google Scholar]
  33. Olsen Geary W., Hansen Kristen J., Stevenson Lisa A., Burris Jean M., Mandel Jeffrey H. Human donor liver and serum concentrations of perfluorooctanesulfonate and other perfluorochemicals. Environ Sci Technol. 2003 Mar 1;37(5):888–891. doi: 10.1021/es020955c. [DOI] [PubMed] [Google Scholar]
  34. Olsen Geary W., Logan Perry W., Hansen Kristen J., Simpson Cathy A., Burris Jean M., Burlew Michele M., Vorarath Phanasouk P., Venkateswarlu Pothapragada, Schumpert John C., Mandel Jeffrey H. An occupational exposure assessment of a perfluorooctanesulfonyl fluoride production site: biomonitoring. AIHA J (Fairfax, Va) 2003 Sep-Oct;64(5):651–659. doi: 10.1202/375.1. [DOI] [PubMed] [Google Scholar]
  35. Oswalt R. M. A review of blood donor motivation and recruitment. Transfusion. 1977 Mar-Apr;17(2):123–135. doi: 10.1046/j.1537-2995.1977.17277151916.x. [DOI] [PubMed] [Google Scholar]
  36. Seacat Andrew M., Thomford Peter J., Hansen Kris J., Clemen Lisa A., Eldridge Sandra R., Elcombe Cliff R., Butenhoff John L. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology. 2003 Feb 1;183(1-3):117–131. doi: 10.1016/s0300-483x(02)00511-5. [DOI] [PubMed] [Google Scholar]
  37. Seacat Andrew M., Thomford Peter J., Hansen Kris J., Olsen Geary W., Case Marvin T., Butenhoff John L. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol Sci. 2002 Jul;68(1):249–264. doi: 10.1093/toxsci/68.1.249. [DOI] [PubMed] [Google Scholar]
  38. Singer L., Ophaug R. H. Concentrations of ionic, total, and bound fluoride in plasma. Clin Chem. 1979 Apr;25(4):523–525. [PubMed] [Google Scholar]
  39. Starkov A. A., Wallace K. B. Structural determinants of fluorochemical-induced mitochondrial dysfunction. Toxicol Sci. 2002 Apr;66(2):244–252. doi: 10.1093/toxsci/66.2.244. [DOI] [PubMed] [Google Scholar]
  40. Taves D. R. Evidence that there are two forms of fluoride in human serum. Nature. 1968 Mar 16;217(5133):1050–1051. doi: 10.1038/2171050b0. [DOI] [PubMed] [Google Scholar]
  41. Thibodeaux Julie R., Hanson Roger G., Rogers John M., Grey Brian E., Barbee Brenda D., Richards Judy H., Butenhoff John L., Stevenson Lisa A., Lau Christopher. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: maternal and prenatal evaluations. Toxicol Sci. 2003 May 28;74(2):369–381. doi: 10.1093/toxsci/kfg121. [DOI] [PubMed] [Google Scholar]
  42. Wood E. M., Kim D. M., Miller J. P. Accuracy of predonation Hct sampling affects donor safety, eligibility, and deferral rates. Transfusion. 2001 Mar;41(3):353–359. doi: 10.1046/j.1537-2995.2001.41030353.x. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES